Analyst Brendan Smith of TD Cowen maintained a Buy rating on Twist Bioscience, reducing the price target to $32.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brendan Smith’s rating is based on a combination of factors that highlight both challenges and opportunities for Twist Bioscience. Despite a reduction in the price target to $32, Smith sees potential in the company’s medium-term outlook, particularly with the stabilization in the Synthetic Biology (SynBio) and Biopharma segments. These areas are expected to grow above prior consensus, indicating a positive trajectory.
Smith acknowledges the current pressures on Twist Bioscience’s stock, primarily due to questions about revenue mix assumptions for FY26. However, he notes that the DNA Synthesis and Protein Solutions segment is well-positioned for sustained growth, driven by the expansion of AI-driven drug discovery tools and increased demand for custom sequences. While near-term growth assumptions for Next-Generation Sequencing (NGS) are tempered, Smith anticipates a significant growth inflection by the fourth quarter of FY26, supporting his Buy rating.
Smith covers the Healthcare sector, focusing on stocks such as Twist Bioscience, Repligen, and Schrodinger. According to TipRanks, Smith has an average return of 12.5% and a 57.14% success rate on recommended stocks.